Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:7 Issue:10 Number:46 ISSN#:2564-2537
RCT
ACE Report #10365
Ace Report Cover Cannabis

Cannabis oralmucosal spray does not significantly improve neuropathic pain from multiple sclerosis


How to Cite

OrthoEvidence. Cannabis oralmucosal spray does not significantly improve neuropathic pain from multiple sclerosis. ACE Report. 2018;7(10):46. Available from: https://myorthoevidence.com/AceReport/Report/10365

Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A

A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis

J Neurol. 2013 Apr;260(4):984-97. doi: 10.1007/s00415-012-6739-4

Contributing Authors: S Ratcliffe W Notcutt RM Langford J Mares A Novotna M Vachova I Novakova

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

In a multicentre randomized trial, 339 patients with central neuropathic pain due to multiple sclerosis (MS) were randomized to receive either an oralmucosal spray containing THC and CBD (nabiximols) or placebo spray for 12 weeks, followed by an open-label and randomized-withdrawal phase for another 14 weeks. The primary outcome was at least 30% pain reduction, and secondary outcomes included time...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE
For Reprints and Permissions, click here

Please Login or Join to leave comments.